检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial

Albert Oriol,Irwindeep Sandhu,Marc Raab,Darrell White,Richard LeBlanc,Noopur Raje,Enrique Ocio,Aurore Perrot,Thierry Facon,Cesar Rodriguez,Ralph Waesch,Michael Amatangelo,Zehua Zhou,Yue Wang,Tiziana Civardi,Philip Koo,Paulo Maciag,Daniel Zhu,Jessica Katz,Paul Richardson

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）

引用 0|浏览15
暂无评分
关键词
relapsed/refractory multiple myeloma,bortezomib,mezigdomide,carfilzomib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要